Revelation Biosciences (REVB) investor relations material

Executive summary

• The annual meeting is scheduled for June 24, 2026, and will be held virtually via Zoom, with voting on three main proposals: election of a director, authorization of reverse stock splits, and ratification of the independent auditor.

• Only shareholders of record as of April 30, 2026, are entitled to vote, with each share representing one vote per proposal.

• The proxy statement includes forward-looking statements subject to risks and uncertainties, referencing risk factors in recent SEC filings.

Voting matters and shareholder proposals

• Shareholders will vote to elect one Class A director (Jennifer Carver) for a term ending at the 2029 annual meeting.

• Authorization is sought for the board to effect one or more reverse stock splits within a one-year period at a ratio between 1-for-2 and 1-for-250.

• Ratification of Baker Tilly US, LLP as the independent auditor for the fiscal year ending December 31, 2026, is proposed.

• The board recommends voting in favor of all proposals.

Board of directors and corporate governance

• The board is classified into three staggered classes, each serving three-year terms; current directors are Jennifer Carver (Class A), James Rolke and Jess Roper (Class B), and Lakhmir Chawla (Class C).

• Three standing committees exist: Audit, Compensation, and Nominating and Governance, each with independent directors and written charters.

• The board has adopted corporate governance guidelines and a code of ethics for all employees and officers.

• All directors except the CEO are considered independent under Nasdaq and SEC rules.